←
Loading live data…
$JNJ$273.07 ▲0.3%
Johnson & Johnson
WHAT THEY DO
Johnson & Johnson is a global healthcare company that sells prescription medicines (oncology, immunology, neuroscience), medical devices used in surgery and orthopedics, and consumer health products. It makes money by selling drugs and devices to hospitals, doctors, insurers and patients worldwide.
💎 CONVERGENCE PLAY — in 2 themes
GLP-1 / ObesityMedTech RoboticsImmunology & Oncology
PRICE
Loading…
REVENUE MIX
Innovative Medicine64%
MedTech36%
COST
COGS32%
R&D16%
SG&A27%
Op Margin26%
FINANCIAL HEALTH
Reported through Sep 27, 2026
Figures are trailing twelve months (TTM) unless marked otherwise.
REVENUE
$99.3B
Growth
6%
QTR YOY
Gross M.
68%
P/E
41.3
EV/EBITDA
19.8
Net M.
16%
FCF M.
19%
D/E
0.59
LATEST QTR
Op M.
26%
PLUG INTO YOUR DCF
Historical growth
2.7%
Analyst 5y growth
—
Forward P/E
23.4
PEG ratio
3.10
Trailing EPS
$6.60
Forward EPS
$11.60
Multiple compressing
Forward P/E is lower than trailing — earnings are expected to grow into the price.
CAPEX & R&D — LAST 0 FISCAL YEARS (SEC FILINGS)
Loading…
TAM
SIZE
$1.9T global healthcare spend by 2030
CAGR
5%
J&J sells into the enormous global pharma and medical device markets, which grow mid-single digits as populations age and emerging markets gain access to care. Growth is concentrated in oncology, immunology, neuroscience and surgical robotics, where pricing and innovation are strongest.
RISK ASSESSMENT
HIGStelara and other key drug patent expirations create a multi-billion dollar revenue cliff that new launches must offset.
MEDLitigation over talc and other product liability claims could produce large settlements and headline risk.
LOWCurrency swings and drug pricing policy changes could trim reported growth modestly.
🐂 BULL
A durable, cash-generative healthcare compounder with a deep oncology and immunology pipeline, rising MedTech margins and a fortress balance sheet that funds steady dividend growth and bolt-on deals.
🐻 BEAR
At roughly 40x trailing earnings the stock already prices in a smooth patent-cliff transition, while Stelara erosion, talc litigation and pricing pressure could keep growth in the mid-single digits and cap multiple expansion.
EARNINGS
EPS · Q3 2026
Beat ✓
REVENUE
Beat ✓
MANAGEMENT TONE
BearishBullish
🔗 IMPACT ON YOUR THESIS
Oncology and immunology pipeline offsets Stelara loss
Watch→On Track
New drug launches beat expectations and narrowed the Stelara gap
MedTech margin recovery and surgical robotics ramp
Watch→On Track
MedTech grew above market with improving operating margins
Talc litigation overhang resolves without major cash hit
Watch→Watch
No new material reserve change; uncertainty persists
AI-powered data, computed by TreasureX · May contain inaccuracies
⚠️
All values, scores, and figures here are computed from your own assumptions and public data, for educational purposes only. This is not investment advice — TreasureX does not recommend buying or selling any security. Results change with your inputs. Please do your own research and use your own judgement before making any investment decision.